Luna18: The Oral Peptide Achieving 47% Bioavailability — A Potential Game-Changer

Peptide therapeutics have historically been confined to parenteral administration — primarily subcutaneous injection — due to the formidable barriers presented by the gastrointestinal tract. Gastric acid (pH 1–3), pepsin, pancreatic proteases, and the tightly regulated epithelial barrier collectively degrade or exclude peptides before they can reach systemic circulation. For the vast majority of peptide compounds, oral bioavailability remains below 1–2%, rendering oral delivery commercially and pharmacologically impractical.

This constraint has shaped the peptide therapeutics market for decades: clinically successful peptides such as insulin, exenatide, and teriparatide all require injection. The inconvenience and patient burden of injectable regimens have driven intense research into oral delivery strategies, yet most approaches yield only marginal improvements in absorption. Against this backdrop, the emergence of Luna18 — a cyclic peptide achieving 21–47% oral bioavailability in preclinical models — represents a step-change in what is considered chemically achievable.

Luna18 (paluratide, CAS 2676177-63-0) is an 11-mer cyclic peptide originally developed by Chugai Pharmaceutical as a pan-RAS inhibitor targeting intracellular KRAS proteins. The compound was discovered through an mRNA display library screening campaign — a technology that enables exploration of vast peptide sequence space (>10^12 unique sequences) to identify hits against challenging intracellular targets.

The initial hit compound, designated AP8747, was identified from the mRNA display library and subsequently underwent extensive chemical optimization. This optimization program, conducted without scaffold hopping, systematically addressed three critical parameters: target binding affinity, membrane permeability, and metabolic stability. Key modifications included identification of peptide side chains that increased RAS affinity more than 10-fold, physicochemical property adjustments through strategic side-chain engineering, and conformational restriction to stabilize the bioactive conformation.

The result was an orally bioavailable macrocyclic peptide capable of engaging an intracellular protein-protein interaction — a target class historically considered undruggable by peptide modalities. Luna18 was published in the Journal of the American Chemical Society in 2023, detailing the full optimization trajectory from library hit to clinical candidate.

The defining characteristic of Luna18 is its oral bioavailability of 21–47% across multiple preclinical species — mice, rats, monkeys, and dogs — achieved without co-formulation with permeation enhancers. This is a critical distinction: most oral peptide programs rely on functional excipients such as SNAC or sodium caprate to transiently increase gastrointestinal permeability. Luna18 achieves high systemic exposure through intrinsic molecular properties alone.

The physicochemical strategy underlying this achievement centers on controlled lipophilicity and conformational rigidity. The cyclic backbone constrains the peptide into a compact, pre-organized structure that minimizes the entropic penalty of membrane partitioning. Strategic N-methylation of specific amide bonds reduces the number of exposed hydrogen bond donors — a key determinant of passive membrane permeability according to established structure-permeability relationships.

• Oral bioavailability ranged from 21% (lowest species) to 47% (highest species) across four preclinical models
• No permeation enhancers, absorption promoters, or specialized formulation vehicles were required
• The cyclic 11-mer structure confers resistance to gastrointestinal proteases through conformational rigidity
• N-methylation and side-chain engineering reduce hydrogen bond donor count, improving passive transcellular permeability
• Molecular weight (~1,200 Da) significantly exceeds traditional Lipinski guidelines yet achieves oral absorption

To contextualize Luna18's achievement, it is instructive to compare oral bioavailability across the current landscape of orally administered peptide and peptide-like therapeutics. The reference compound for oral peptide delivery is semaglutide (marketed as Rybelsus), which achieves approximately 0.8–1% oral bioavailability when co-formulated with 300 mg of the permeation enhancer SNAC (salcaprozate sodium). Despite this low absolute bioavailability, oral semaglutide delivers clinically meaningful efficacy through high intrinsic potency.

At the other end of the spectrum, orforglipron (LY3502970, Eli Lilly) achieves approximately 79% oral bioavailability. However, orforglipron is a non-peptide small molecule — a synthetic GLP-1 receptor agonist that circumvents the peptide delivery problem entirely through its small-molecule chemical architecture. It is chemically stable in gastric acid, resistant to proteolytic degradation, and crosses epithelial barriers through conventional passive diffusion.

Luna18 occupies a unique intermediate position: it is a bona fide peptide (11 amino acid residues, cyclic backbone) yet achieves bioavailability that approaches small-molecule territory. This positions Luna18 not as a direct therapeutic competitor to GLP-1 agonists, but as a proof-of-concept that macrocyclic peptides can be engineered for high oral exposure through systematic molecular design.

While Luna18 achieves oral absorption without excipient assistance, most oral peptide programs rely on functional permeation enhancers — most notably SNAC (salcaprozate sodium, or sodium N-[8-(2-hydroxybenzoyl)amino] caprylate) and sodium caprate (C10). Understanding these mechanisms provides context for why Luna18's enhancer-independent absorption is noteworthy.

SNAC operates through a multifactorial mechanism in the gastric environment. Upon tablet dissolution, SNAC creates a localized pH increase that reduces pepsinogen-to-pepsin conversion, protecting the co-formulated peptide from enzymatic degradation. Simultaneously, SNAC promotes monomerization of the peptide payload by modifying local polarity, and increases transcellular permeability through membrane fluidization. A 2025 Nature Communications study using continuous constant-pH molecular dynamics (CpHMD) simulations revealed that SNAC induces fluid, SNAC-filled membrane defects rather than simple bilayer fluidization — a mechanism more nuanced than previously understood.

Sodium caprate (C10) operates through a complementary mechanism, primarily enhancing paracellular permeability by transiently opening tight junctions between epithelial cells. Recent preclinical and clinical studies have demonstrated that combining SNAC and C10 in oral tablet formulations produces synergistic permeability enhancement — significantly greater than either agent alone — suggesting that dual transcellular and paracellular pathway modulation represents an optimal strategy for peptide absorption.

Beyond chemical permeation enhancers, formulation science provides complementary strategies to protect peptide integrity during gastrointestinal transit. Enteric coatings — pH-responsive polymer films that remain intact in gastric acid (pH 1–3) but dissolve in the higher pH of the duodenum and jejunum (pH 5.5–7) — prevent premature peptide degradation and target release to intestinal absorption windows.

Microparticle and nanoparticle delivery systems offer an additional layer of protection. Encapsulation within biodegradable polymer matrices (such as PLGA or chitosan-based systems) shields peptides from enzymatic attack while enabling sustained release at the absorption site. These systems can be further engineered with mucoadhesive surface coatings that prolong contact time with the intestinal epithelium, enhancing the probability of transepithelial transport.

• Enteric coatings (e.g., Eudragit L, HPMCP) bypass gastric degradation by dissolving only at intestinal pH
• PLGA microparticles provide sustained peptide release and protection from luminal proteases
• Chitosan-based nanoparticles offer mucoadhesive properties that extend epithelial contact time
• Lipid-based formulations (SEDDS, liposomes) enhance lymphatic uptake and bypass hepatic first-pass metabolism
• Combination strategies layering enteric coating over enhancer-loaded microparticles show additive effects in preclinical models

MK-0616, developed by Merck, provides a complementary case study in oral peptide delivery. This macrocyclic peptide inhibitor of PCSK9 (proprotein convertase subtilisin/kexin type 9) was discovered through mRNA display technology and optimized for oral bioavailability through iterative medicinal chemistry. MK-0616 binds PCSK9 with a Ki of 5 pM and demonstrated sufficient oral bioavailability in preclinical models to enable clinical advancement.

In Phase 1 clinical studies, single oral doses of MK-0616 achieved greater than 93% geometric mean reduction of free, unbound plasma PCSK9 in healthy adults. Phase 2b results demonstrated statistically significant LDL-C reductions compared to placebo, with greater than 55% placebo-adjusted reduction at doses of 12 mg and higher. These results are particularly striking given that MK-0616 operates at relatively low absolute oral bioavailability — demonstrating that ultra-high target affinity can compensate for limited systemic exposure.

The MK-0616 program illustrates an important principle: absolute bioavailability is not the sole determinant of oral peptide viability. When combined with picomolar binding affinity and favorable pharmacokinetics (including a long elimination half-life), even modest oral absorption can yield therapeutically relevant drug concentrations. This principle expands the design space for oral peptide programs beyond the traditional focus on maximizing percent bioavailability.

Luna18, MK-0616, and the iterative refinement of SNAC-based formulations collectively signal that oral peptide delivery is transitioning from a theoretical aspiration to an engineering discipline. The key advances driving this shift include: mRNA display and related high-throughput screening platforms that access vast macrocyclic sequence space; computational tools for predicting membrane permeability of beyond-Rule-of-5 compounds; and mechanistic understanding of enhancer-membrane interactions at the molecular dynamics level.

Several technical frontiers remain. First, the translation of preclinical bioavailability to human pharmacokinetics remains unpredictable — species-dependent differences in gastrointestinal physiology, transit time, and transporter expression introduce variability that preclinical models do not fully capture. Second, food effects represent a persistent challenge: oral semaglutide must be administered in a fasting state with restricted water intake, a dosing regimen that impacts patient compliance.

Third, manufacturing scalability of complex macrocyclic peptides at pharmaceutical grade remains nontrivial compared to small molecules. The synthesis of constrained cyclic peptides with multiple N-methylated residues and non-natural amino acids requires specialized solid-phase or solution-phase chemistry that is inherently more costly than conventional small-molecule synthesis.

From an analytical perspective, Luna18 represents a benchmark compound for laboratories investigating oral peptide absorption mechanisms. Its intrinsic permeability — achieved without formulation assistance — makes it a valuable reference standard for Caco-2 permeability assays, parallel artificial membrane permeability assays (PAMPA), and in situ intestinal perfusion studies. Researchers studying structure-permeability relationships in macrocyclic peptide space will find Luna18's published physicochemical and pharmacokinetic data an essential point of comparison for novel macrocyclic scaffolds under development.

Explore detailed chemical profiles and research guides for compounds discussed in this article:

• Orforglipron: Complete Research Guide → /learn/orforglipron-research-guide-chemical-profile
• Semaglutide: Complete Research Guide → /learn/semaglutide

• Read more: Pinnacle Medicines Raises $89M for Next-Generation Oral Peptides → https://www.chemverify.com/learn/pinnacle-medicines-raises-89m-oral-peptides
• Read more: Orforglipron FDA Approval April 2026: First Oral GLP-1 Without Food Restrictions → https://www.chemverify.com/learn/orforglipron-fda-approval-april-2026
• Read more: ICOTYDE (Icotrokinra): First Targeted Oral Peptide for Plaque Psoriasis — FDA Approved → https://www.chemverify.com/learn/icotyde-icotrokinra-fda-approved-oral-peptide-plaque-psoriasis
• Read more: Unnatural Products and Novartis: A $1.7 Billion Deal for Synthetic Macrocyclic Peptides → https://www.chemverify.com/learn/unnatural-products-novartis-1-7-billion-macrocyclic-peptides-deal